Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Completed · Phase 1/Phase 2
Conditions studied: Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
In brief
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
Key facts
- Study ID
- NCT05259696
- Run by
- Palleon Pharmaceuticals, Inc.
- People needed
- 69
- Starts
- 2022-02-11
- Expected to finish
- 2024-10-24
- Last updated by the study team
- 2025-08-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UC San Diego Moores Cancer Center — La Jolla, California, United States
- University of Southern California — Los Angeles, California, United States
- Stanford Health Care — Stanford, California, United States
- Yale University Cancer Center — New Haven, Connecticut, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- START Midwest — Grand Rapids, Michigan, United States
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
- Columbia University — New York, New York, United States
- Providence Cancer Institute — Portland, Oregon, United States
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- NEXT Oncology — San Antonio, Texas, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.